Loading…
← CockpitCompetitor Analysis › 603255.SS Liaoning Dingjide Petrochemical Co., Ltd. Class AOpen in the cockpit ↗

Liaoning Dingjide Petrochemical Co., Ltd. Class A603255.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology
Momentum neutral 46
Mkt cap
$490M
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$6.20M
20-day average traded
Fwd P/E
37.5×
forward earnings
ROIC−WACC
-3.9 pp
WACC 5.7%
Hurdle
n/a
no reverse DCF
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥24.71
1D-2.5%
1W-6.7%
1M-18.1%
3M-13.4%
6M-24.2%
YTD-15.7%
1Y-24.6%
ATR %6.4%
52w lowhigh35.8% off high

What Liaoning Dingjide Petrochemical does

Employees: 1,221

Liaoning Dingjide Petrochemical at a glance

Size Liaoning Dingjide Petrochemical (603255.SS) is a China Health Care company (Biotechnology) with a market value of $490M, the 3747th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥24.71 on 18 Nov 2026.

Performance Over six months the shares fell 24.2%, against -1.9% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 18 in its peer set.

Growth Revenue grew 70.4% over the last twelve months (peer median -4.0%); the operating margin is 4.6% (peer median -22.0%).

Valuation It trades at 37.5× forward earnings against a peer median of 17.9× (most expensive of 6).

Capital Return on invested capital runs 3.9 points below its cost of capital (5.7% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 103603255.SS 75
Six months, rebased to 100: Liaoning Dingjide Petrochemical against the median of its 20 peers (local-currency closes).

Liaoning Dingjide Petrochemical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.45BCN¥839MCN¥778MCN¥755MCN¥899M
Revenue growth—+8%+3%-16%—
Gross profitCN¥274MCN¥103MCN¥96.3MCN¥153MCN¥211M
EBITDAn/aCN¥106MCN¥51.5MCN¥121MCN¥164M
Net incomeCN¥53.1MCN¥11.4M-CN¥12.1MCN¥61.4MCN¥110M
Free cash flow-CN¥238M-CN¥2.60B-CN¥1.40B-CN¥132M-CN¥61.4M
Capital expenditureCN¥608MCN¥2.45BCN¥1.53BCN¥245MCN¥99.4M
Total debtCN¥3.86BCN¥3.57BCN¥1.19BCN¥288MCN¥74.6M

Quarterly statements and history in the cockpit →

Liaoning Dingjide Petrochemical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+50%+100%6586688247CBIO4147MNPRNGNEVLAFENCDMAC300318STTK04196011518065891521603255.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Liaoning Dingjide Petrochemical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%20×30×300858FENCKMDA1521603255.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Liaoning Dingjide Petrochemical is the large dot.

Liaoning Dingjide Petrochemical competitors and peer comparison

How Liaoning Dingjide Petrochemical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Liaoning Dingjide Petrochemical against its 20 peers (data as of 18 Nov 2026)
Measure603255.SSPeer medianRank in peer set
1-month return-18.1%-9.5%7th lowest of 21
6-month return-24.2%-1.9%5th lowest of 18
Distance from 52-week high-35.8%-44.6%8th highest of 21
Revenue growth (TTM)+70.4%-4.0%2nd highest of 15
Operating margin4.6%-22.0%5th highest of 15
Forward P/E37.5×17.9×most expensive of 6
ROIC minus cost of capital-3.9 pp-5.8 pp5th highest of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%37.5×n/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%n/an/an/a
Sinotherapeutics 688247.SSChina$494M-19%-17%0%n/a29.4%+7.0%
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%n/an/an/a
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%n/an/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%21.5×n/an/a
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%n/an/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%16.9×58.8%+204.7%
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Kamada KMDAUnited States$465M+3%+5%15%17.9×5.0%+6.5%
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%n/an/an/a
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%2.3×n/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%n/an/an/a
Qurient 115180.KSSouth Korea$452M-56%-14%-512%n/an/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%n/an/an/a
Frontage 1521.HKHong Kong$542M+113%+10%8%24.6×14.3%+15.4%

Questions

Which companies are Liaoning Dingjide Petrochemical's closest peers?
The cockpit's peer set: CHO Pharma (6586.TWO), Sinotherapeutics (688247.SS), Crescent Biopharma (CBIO), TaiMed Biologics (4147.TWO), Monopar Therapeutics (MNPR), Beijing Scitop Bio-Tech (300858.SZ), Neurogene (NGNE), Valneva (VLA.PA).
Is Liaoning Dingjide Petrochemical expensive compared with its peers?
On forward p/e it trades at 37.5× against a peer median of 17.9×, most expensive of 6 in its peer set.
How has Liaoning Dingjide Petrochemical stock performed?
Over six months to 18 Nov 2026 the shares returned -24.2% against -1.9% for the median peer; over one year -24.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.